Search results
Why Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term
Zacks via Yahoo Finance· 11 hours agoThis Score can pinpoint good times to build a position in a stock, using factors like one-week price...
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
Zacks via Yahoo Finance· 6 days agoBiogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA...
Ionis, Biogen Down on Ending Development of ALS Drug - Biogen (NASDAQ:BIIB), Heron Therapeutics...
Benzinga· 4 days agoShares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market...
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed...
Benzinga· 6 hours agoLarimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for...
Biogen and Ionis halt ALS drug development after trial setback By Investing.com
Investing.com· 5 days agoBiogen Inc. (NASDAQ:BIIB) and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) have announced the...
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic...
Morningstar· 6 days agoBiogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense ...
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
Market Watch· 5 days ago“However, over the 6-month placebo-controlled period, treatment with BIIB105 did not result in a...
Avadel Pharmaceuticals appoints new board member By Investing.com
Investing.com· 8 hours agoAvadel Pharmaceuticals plc (NASDAQ:AVDL), a company specializing in developing innovative...
Press Releases
Morning Times· 6 days ago(Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") ...
Biogen, Ionis to discontinue development of ALS drug
Reuters· 6 days ago, opens new tab said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after...